NCT06098651已完成1 期
An Open-label, Phase 1, Dose-ranging Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenous DCR-STAT3 in Adults With Refractory Solid Tumors
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company1 个研究点 分布在 1 个国家目标入组 26 人开始时间: 2023年8月14日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 26
- 试验地点
- 1
- 主要终点
- Severity of adverse events
研究概览
简要总结
This is a sequential, ascending-dose, multicenter study conducted in patients with refractory solid tumors designed to evaluate the safety, tolerability, and pharmacokinetics of DCR-STAT3.
详细描述
The primary goal of this first-in-human study is to assess the safety and tolerability of DCR-STAT3 in adults with refractory solid tumors. Secondary study goals are to evaluate potential antitumor effects of STAT3 knockdown, as assessed by circulating blood biomarkers indicative of immune activation, as well as any direct impact on tumor size by appropriate imaging and RECIST 1.1 criteria. Antitumor effects will be evaluated for DCR-STAT3 as a monotherapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •≥ 18 years of age inclusive, at the time of signing the informed consent.
- •Type of Participant and Disease Characteristics
- •- Documented locally advanced or metastatic solid tumor malignancy or non-Hodgkin's lymphoma that is refractory to standard therapy known to provide clinical benefit for their condition or for which no standard therapy is available
- •Demonstrated evidence of disease progression, via imaging, during or following standard therapy known to provide clinical benefit for their condition
- •Demonstrated intolerance to standard therapy known to provide clinical benefit for their condition
- •Measurable disease according to RECIST version 1.1 (as determined by CT or MRI)
- •Malignancy not currently amenable to surgical intervention due to medical contraindication or non-resectability of the tumor
- •ECOG performance status of 0, 1, or 2, and an anticipated life expectancy of ≥ 3 months
- •- BMI ≥ 18 kg/m2
- •Male participants are eligible to participate if they agree to the following during the study intervention period and for at least 24 weeks after the last dose of study intervention:
- •Refrain from donating sperm
- •AND, either:
- •Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent OR
- •Must agree to use a male condom when having sexual intercourse with a WOCBP who is not currently pregnant
- •Female participants are eligible to participate if they are not pregnant or breastfeeding, and one of the following conditions applies:
- •Is not a WOCBP OR
- •Is a WOCBP and:
- •is using a contraceptive method that is highly effective, with a failure rate of < 1%, as described in Section 10.4 during the study intervention period and for at least 24 weeks after the last dose of study intervention. The Investigator should evaluate the potential for contraceptive method failure (e.g., noncompliance, recently initiated) in relationship to the first dose of study intervention.
- •must have a negative highly sensitive pregnancy test (serum as required by local regulations) on Day 1 of each cycle before the first dose of study intervention
排除标准
- •Prior/Concomitant Therapy
- •- Other concurrent (within 28 days of Day 1, Cycle 1) chemotherapy, immunotherapy, or radiotherapy. Note that hormonal therapy (e.g., tamoxifen, LHRH agonists) is allowed.
- •- Requirement for palliative radiotherapy to lesions that are defined as target lesions by RECIST version 1.1 criteria at the time of study entry
- •Continued compromise or inadequate recovery from a prior anti-neoplastic therapy
- •Known hypersensitivity to any of the components of DCR-STAT3
- •Long-term immunosuppressive therapy
- •Prior/Concurrent Clinical Study Experience
- •Treatment with investigational therapy(ies) within 5 half-lives of the investigational therapy prior to the first scheduled day of dosing with DCR-STAT3, or 4 weeks if the half-life of the investigational agent is not known
- •Diagnostic assessments - Seropositive for antibodies to HIV, HBV, or HCV at Screening (historical testing may be used if performed within the 3 months prior to screening). NOTE: In participants with previous treatment for hepatitis C with direct-acting HCV medication and seropositivity for HCV, or in participants with prior infection and spontaneous resolution, HCV RNA must be undetectable (at least 2 negative HCV RNA tests at least 12 weeks apart), and the HCV infection must have been resolved or cured > 3 years prior to initial dosing with the investigational medication.
研究组 & 干预措施
DCR-STAT3
Experimental
DCR-STAT3
干预措施: DCR-STAT3 (Drug)
结局指标
主要结局
Severity of adverse events
时间窗: Cycle 1 (8 weeks)
measured according to CTCAE 5.0 criteria
Incidence of adverse events and dose limiting toxicities
时间窗: Cycle 1 (8 weeks)
safety and tolerability
次要结局
- Pharmacokinetic (AUC)(Day 1 and Day 29 of Cycle 1 (each cycle is 8 weeks))
- Pharmacokinetic (Urine)(Day 1 and Day 29 of Cycle 1 (each cycle is 8 weeks))
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Phase 1 Dose Escalation Study of AV-203, an ERBB3 Inhibitory Antibody, in Subjects With Advanced Solid TumorsSolid TumorsNCT01603979AVEO Pharmaceuticals, Inc.24
招募中
1 期
Clinical Study of T3011 Intravesical Instillation for Treatment of NMIBC PatientsBladder CancerNCT06427291Fudan University20
已完成
1 期
A Study of CS1002 in Subjects With Advanced Solid TumorsSolid Tumor, AdultNCT03523819CStone Pharmaceuticals91
招募中
1 期
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid TumorsMetastatic Solid TumorAdvanced or Metastatic Solid TumorNCT06270706Pliant Therapeutics, Inc.124
已完成
1 期
A Phase 1 Study of SAIL66 in Patients With CLDN6-positive Locally Advanced or Metastatic Solid TumorsSolid TumorNCT05735366Chugai Pharmaceutical22